发布时间：2025-12-19 09:16 Pivotal Phase 3 studies of once-daily oral zasocitinib met all primary and ranked secondary endpoints in patients with moderate-to-severe plaque psoriasis
More than half of study participants treated with zasocitinib achieved clear or almost clear skin (PASI 90), and on average about 30 percent achieved completely clear skin (PASI 100) by week 16
Zasocitinib was generally well-tolerated with a safety profile consistent with previous clinical studies
OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda(TSE:4502/NYSE:TAK)today announced positive topline results for the two pivotal Phase 3randomized, multicenter, double-blind, placebo- and active comparator-controlled studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO). The studies demonstrated superiority of zasocitinib compared to placebo for the co-primary endpoints, static Physici
=*=*=*=*=*=
当前为第1/20页
下一页-
=*=*=*=*=*=
返回新闻列表
返回网站首页